Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Licitra

Showing results (281-290 of 311) with videos related to

Pageof 32
Sort By:
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Oral Oncology|July 27, 2019
Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancerEtienne Dauzier, Benjamin Lacas, Pierre Blanchard, et al.
Critical Reviews in Oncology/Hematology|March 31, 2015
Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensusAurora Mirabile, Gianmauro Numico, Elvio G Russi, et al.
The Journal of Clinical Investigation|September 25, 2025
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation doseEmily Ho, Loris De Cecco, Steven A Eschrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> MutationsAlan L Ho, Irene Brana, Robert Haddad, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2022
Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258]Alice Baggi, Pietro Quaglino, Marco Rubatto, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinomaAlice Baggi, Pietro Quaglino, Marco Rubatto, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2021
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trialRachel Galot, Christophe Le Tourneau, Esma Saada-Bouzid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Cancer Research|February 19, 2015
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer PatientsAbdullah A Osman, David M Neskey, Panagiotis Katsonis, et al.
Pageof 32

Showing results (281-290 of 311) with videos related to

Sort By:
Pageof 32
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Oral Oncology|July 27, 2019
Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancerEtienne Dauzier, Benjamin Lacas, Pierre Blanchard, et al.
Critical Reviews in Oncology/Hematology|March 31, 2015
Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensusAurora Mirabile, Gianmauro Numico, Elvio G Russi, et al.
The Journal of Clinical Investigation|September 25, 2025
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation doseEmily Ho, Loris De Cecco, Steven A Eschrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> MutationsAlan L Ho, Irene Brana, Robert Haddad, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2022
Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258]Alice Baggi, Pietro Quaglino, Marco Rubatto, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinomaAlice Baggi, Pietro Quaglino, Marco Rubatto, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2021
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trialRachel Galot, Christophe Le Tourneau, Esma Saada-Bouzid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Cancer Research|February 19, 2015
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer PatientsAbdullah A Osman, David M Neskey, Panagiotis Katsonis, et al.
Pageof 32